Comparative Pharmacology
Head-to-head clinical analysis: EMFLAZA versus PREDNISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMFLAZA versus PREDNISONE.
EMFLAZA vs PREDNISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response.
Agonist at glucocorticoid receptors, leading to altered gene transcription that results in anti-inflammatory and immunosuppressive effects, including suppression of cytokines, prostaglandins, and leukotrienes.
0.6 mg/kg orally once daily (maximum 60 mg/day); titrate to lowest effective dose based on clinical response.
5-60 mg orally once daily or divided twice daily; for acute indications, initial dose 5-60 mg/day; for chronic conditions, lowest effective dose; route: oral, intravenous, intramuscular.
None Documented
None Documented
6.2 hours (range 4.5–8.1 h) in healthy adults; prolonged in hepatic impairment.
Clinical Note
moderatePrednisone + Digoxin
"Prednisone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderatePrednisone + Digitoxin
"Prednisone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderatePrednisone + Deslanoside
"Prednisone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderatePrednisone + Acetyldigitoxin
"Prednisone may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: 2-3 hours (plasma); clinical effects persist for 12-36 hours due to intracellular actions and active metabolite prednisolone (half-life 3-4 hours).
Renal excretion of inactive metabolites; less than 5% excreted as unchanged drug in urine. Biliary/fecal elimination accounts for <1%.
Renal: <10% as unchanged drug; hepatic metabolism to inactive glucuronide and sulfate conjugates; fecal: ~20-30% via biliary elimination.
Category C
Category D/X
Corticosteroid
Corticosteroid